138 related articles for article (PubMed ID: 9636014)
1. Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients.
Carles J; Domenech M; Gelabert-Mas A; Nogue M; Tabernero JM; Arcusa A; Guasch I; Miguel A; Ballesteros JJ; Fabregat X
Acta Oncol; 1998; 37(2):187-91. PubMed ID: 9636014
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer.
Colleoni M; Graiff C; Vicario G; Nelli P; Sgarbossa G; Pancheri F; Manente P
Am J Clin Oncol; 1997 Aug; 20(4):383-6. PubMed ID: 9256895
[TBL] [Abstract][Full Text] [Related]
3. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
[TBL] [Abstract][Full Text] [Related]
4. Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study.
Smith MR; Kaufman D; Oh W; Guerin K; Seiden M; Makatsoris T; Manola J; Kantoff PW
Cancer; 2000 Oct; 89(8):1824-8. PubMed ID: 11042579
[TBL] [Abstract][Full Text] [Related]
5. A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer.
Sweeney CJ; Monaco FJ; Jung SH; Wasielewski MJ; Picus J; Ansari RH; Dugan WM; Einhorn LH
Ann Oncol; 2002 Mar; 13(3):435-40. PubMed ID: 11996476
[TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience.
Pectasides D; Pectasides E; Papaxoinis G; Koumarianou A; Psyrri A; Xiros N; Tountas N; Kamposioras K; Papatsibas G; Floros T; Gouveris P; Karageorgopoulou S; Economopoulos T
Anticancer Res; 2009 Feb; 29(2):769-75. PubMed ID: 19331234
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer.
Borrega P; Velasco A; Bolaños M; del Mar Perez M; Mel JR; Reina JJ; Rodríguez-Jaraiz MA; Chaves M; González-Barón M
Urol Oncol; 2004; 22(1):32-5. PubMed ID: 14969801
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.
Hudes GR; Nathan F; Khater C; Haas N; Cornfield M; Giantonio B; Greenberg R; Gomella L; Litwin S; Ross E; Roethke S; McAleer C
J Clin Oncol; 1997 Sep; 15(9):3156-63. PubMed ID: 9294479
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone-refractory prostate cancer.
Koletsky AJ; Guerra ML; Kronish L
Cancer J; 2003; 9(4):286-92. PubMed ID: 12967139
[TBL] [Abstract][Full Text] [Related]
10. An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer.
Vaishampayan U; Fontana J; Du W; Hussain M
Urology; 2002 Dec; 60(6):1050-4. PubMed ID: 12475668
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targeting.
Sewak S; Chachoua A; Hamilton A; Taneja S; Lee J; Utate M; Sorich J; Muggia FM
Anticancer Drugs; 2003 Jan; 14(1):67-72. PubMed ID: 12544260
[TBL] [Abstract][Full Text] [Related]
12. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
[TBL] [Abstract][Full Text] [Related]
13. The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.
Samelis GF; Kalofonos H; Adamou A; Kosmides P; Skarlos D; Aravantinos G; Kiamouris C; Adimchi O; Fountzilas G; Dimopoulos AM
Urology; 2005 Aug; 66(2):382-5. PubMed ID: 16098366
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.
Kreis W; Budman DR; Fetten J; Gonzales AL; Barile B; Vinciguerra V
Ann Oncol; 1999 Jan; 10(1):33-8. PubMed ID: 10076719
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer.
Smith DC; Esper P; Strawderman M; Redman B; Pienta KJ
J Clin Oncol; 1999 Jun; 17(6):1664-71. PubMed ID: 10561202
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer.
Carles Galcerán J; Bastus Piulats R; Martín-Broto J; Maroto Rey P; Nogué Aligué M; Domenech Santasusana M; Arcusa Lanza A; Bellmunt Molins J; Colin C; Girard A
Clin Transl Oncol; 2005 Mar; 7(2):66-73. PubMed ID: 15899211
[TBL] [Abstract][Full Text] [Related]
17. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.
Pienta KJ; Redman B; Hussain M; Cummings G; Esper PS; Appel C; Flaherty LE
J Clin Oncol; 1994 Oct; 12(10):2005-12. PubMed ID: 7523606
[TBL] [Abstract][Full Text] [Related]
18. Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).
Kattan JG; Farhat FS; Chahine GY; Nasr FL; Moukadem WT; Younes FC; Yazbeck NJ; Ghosn MG;
Invest New Drugs; 2008 Feb; 26(1):75-9. PubMed ID: 17846704
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of vinorelbine and estramustine in combination with conformational radiotherapy for patients with high-risk prostate cancer.
Carles J; Nogue M; Sole JM; Foro P; Domenech M; Suarez M; Gallardo E; García D; Ferrer F; Gelabert-Mas A; Gayo J; Fabregat X
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1085-91. PubMed ID: 19577864
[TBL] [Abstract][Full Text] [Related]
20. Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma.
Mackler NJ; Pienta KJ; Dunn RL; Cooney KA; Redman BG; Olson KB; Fardig JE; Smith DC
Clin Genitourin Cancer; 2007 Jun; 5(5):318-22. PubMed ID: 17645828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
